{"id":"W4226197684","doi":"10.1177/13524585221083194","title":"Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"Sanofi Genzyme; Innosuisse - Schweizerische Agentur für Innovationsförderung; European Commission; Sanofi; Bayer HealthCare; Eli Lilly and Company; CSL Behring; Biogen; Merck KGaA; Teva Pharmaceutical Industries; Novartis; Pfizer; National Research Foundation","keywords":"Medicine; Placebo; Hazard ratio; Internal medicine; Multiple sclerosis; Confidence interval; Pathology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005187674,0.0001738552,0.0004431078,0.0003005517,0.0001685068,0.00003354242,0.0003104661,0.00006494304,0.00003414693],"category_scores_gemma":[0.0001875198,0.0001572297,0.00006560943,0.0004092144,0.0001037791,0.00002530686,0.000658949,0.0002078521,1.00678e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001718921,"about_ca_system_score_gemma":0.00006615546,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003028436,"about_ca_topic_score_gemma":0.00006844235,"domain_scores_codex":[0.9983529,0.0001223459,0.0004825591,0.0004620718,0.00033751,0.0002426264],"domain_scores_gemma":[0.998823,0.00005576221,0.0003528665,0.0004687213,0.000145764,0.0001539216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002555802,0.0002122614,0.7620742,0.00001881546,0.0003606463,0.000002779114,0.000555839,0.001037774,0.2171069,3.751364e-7,0.00003220865,0.01604234],"study_design_scores_gemma":[0.007057984,0.0004898764,0.9848661,0.0001322255,0.0002754396,0.000005734795,0.0002266654,0.0005776698,0.006153754,4.48211e-7,0.00003522211,0.0001788788],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969178,0.002019797,0.0001617475,0.00001139124,0.00009610281,0.0003266129,0.0004619091,0.000003300112,0.000001323244],"genre_scores_gemma":[0.998356,0.0003150021,0.000840977,0.00005415253,0.00004559564,0.00001109083,0.0003497755,0.00002319982,0.000004217359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2227919,"threshold_uncertainty_score":0.6411643,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04661293181743509,"score_gpt":0.2567185930640929,"score_spread":0.2101056612466579,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}